The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders
Bipolar Disorder

Interventions

DRUG: Sibutramine

Sponsor

Eli Lilly and Company